Seeking Alpha

Sanofi reportedly halts sales of cholesterol drug Praluent in China amid limited availability

Sanofi (NASDAQ:SNY) has stopped shipping its anti-cholesterol therapy Praluent, developed with Regeneron (NASDAQ:REGN), as surging demand has caused availability issues, Reuters reported on Tuesday, ...
AOL

Amgen owes $406 million for monopolizing cholesterol drug market, US jury says

(Reuters) -A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for engaging in anticompetitive behavior to increase sales of its ...
Seeking Alpha

Regeneron wins over $400M jury award as Amgen found liable in antitrust case

A federal jury in Delaware has awarded Regeneron (NASDAQ:REGN) more than $400M in damages after finding that Amgen (NASDAQ:AMGN) violated U.S. antitrust laws by forcing pharmacy benefit managers ...
Nasdaq

Regeneron Pharmaceuticals Celebrates Jury Verdict Against Amgen for Antitrust Violations, Awarding $406.8 Million in Damages

A jury found Amgen liable for antitrust violations, awarding Regeneron $406.8 million in damages related to Praluent competition. A federal court jury in Delaware has ruled that Amgen Inc. violated ...
Reuters

Cigna makes deals with Amgen, Sanofi for pricey cholesterol drugs

NEW YORK, May 11 (Reuters) - Cigna Corp signed deals that will pay the makers of two potent but pricey cholesterol-lowering treatments based on how well their customers respond to the medications, the ...